Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.160
-0.020 (-1.69%)
At close: Jul 13, 2026, 4:00 PM EDT
1.170
+0.010 (0.86%)
After-hours: Jul 13, 2026, 4:38 PM EDT
Alzamend Neuro Employees
As of January 31, 2026, Alzamend Neuro had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees decreased by 1 or -14.29% compared to the same quarter last year.
Employees
6
Change
-1
Growth
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,257,455
Market Cap
4.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jan 31, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Oct 31, 2025 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2025 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2025 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2025 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2024 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2024 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2024 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2024 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2023 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Apr 30, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Jan 31, 2023 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2022 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Apr 30, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Jan 31, 2022 | 7 | 3 | 75.00% | 3 | 4 |
| Oct 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| PMGC Holdings | 34 |
| Aptevo Therapeutics | 33 |
| GeoVax Labs | 19 |
| FibroBiologics | 15 |
| Ensysce Biosciences | 10 |
| Enveric Biosciences | 6 |
| 60 Degrees Pharmaceuticals | 3 |
ALZN News
- 3 months ago - Alzamend Neuro’s AL001 shows “encouraging” data in Phase II brain trial - TheFly
- 3 months ago - Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - PRNewsWire
- 3 months ago - Alzamend Neuro reports ‘positive’ data from Phase II clinical trial of AL001 - TheFly
- 3 months ago - Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - PRNewsWire
- 3 months ago - Alzamend Neuro Slides: Corporate presentation - Filings
- 4 months ago - Alzamend Neuro initiates Phase II trial of AL001 study - TheFly
- 4 months ago - Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - PRNewsWire
- 4 months ago - Alzamend Neuro Quarterly report: Q3 2026 - Filings